Algorithm of anemia correction in oncological patients
https://doi.org/10.17650/2782-3202-2023-3-1-68-72
Abstract
Anemia is one of the most frequent manifestations of oncological diseases and complications of cytotoxic chemotherapy. Development of this symptom is directly associated with decreased quality of life and possible stimulation of neoangiogenesis, increased tumor aggressiveness and decreased tumor sensitivity to chemotherapy and radiation. Current clinical trial data show decreased overall survival of patients with anemia. Modern methods of anemia correction in oncological diseases include exchange transfusion and administration of recombinant erythropoietins. Transfusion of erythrocyte-containing blood components allow to quickly replenish hemoglobin level, however there is risk of complications. A significant disadvantage of this method is short duration of the effect. Use of erythropoietins allows to reliably increase hemoglobin levels in 60–70 % of oncological patients with long-term effect. In recent years, use of erythropoietins in patients with oncological diseases became a topic of discussion due to possible negative effect on tumor through stimulation of erythropoietin receptors on neoplastic cells. This discussion led to recommendation of using erythropoietins only during chemotherapy in minimal doses.
About the Author
J. A. Chekini
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
Jennet Ashirovna Chekini
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
References
1. Ludwig H., Van Belle S., Barret-Lee P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40(15):2293–306. DOI: 10.1016/j.ejca.2004.06.019
2. Caro J.J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91(12):2214–21.
3. Khorana A., Francis C., Blumberg N. et al. Blood transfusions, thrombosis and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168(21):2377–81. DOI: 10.1001/archinte.168.21.2377
4. Osterborg A. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol 1998;15(Suppl 1):S47–9.
5. Ludwig H., Fritz E., Kotzmann H. et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Eng J Med 1990;322(24):1693–9. DOI: 10.1056/NEJM199006143222402
6. Nishii K., Suzuki Y., Minami N. et al. Successful treatment of aplastic anemia with G-CSF and high dose erythropoietin. Leuk Lymphoma 1998;30(1–2):211–4. DOI: 10.3109/10428199809050946
7. Bohlius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: update meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98(10):708–14. DOI: 10.1093/jnci/djj189
8. Agency for Healthcare Research and Quality, Guidelines. 2006.
9. Bennett C.L., Silver S.M., Djulbegovic B. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299(8):914–24. DOI: 10.1001/jama.299.8.914
10. Bolhius J., Schmidlin K., Brillantet C. et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a metaanalysis of randomised trials. Lancet 2009;373(9674):1532–42. DOI: 10.1016/S0140-6736(09)60502-X
11. Delarue R., Haioun C., Coiffier B. et al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study. J Clin Oncol 2011;29(15 suppl): 9048.
12. Nitz U., Gluz O., Oberhoff C. Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective randomized WSG ara plus trial. Cancer Res 2011;71(24 Suppl);PD07–06. DOI: 10.1158/0008-5472.SABCS11-PD07-06
13. Anaemia in malignant diseases. Clinical recommendations of the Association of Oncologists of Russia. (In Russ.). Available at: https://oncology-association.ru/wp-content/uploads/2022/04/ anemiya-pri-zlokachestvennyh-novoobrazovaniyah.pdf
14. Vladimirova L.Yu., Abramova N.A., Lyanova A.A. et al. Epoetin alpha in the treatment of anemia in patients with malignant solid tumors during antitumor drug therapy. Meditsinskiy Sovet = Medical Counsil 2022;16(9):117–25. (In Russ.). DOI: 10.21518/2079-701X-2022-16-9-117-125
15. Bolshakova S.A., Bychkov Yu.M., Kazarova M.V. Own experience of treatment by epoetin- α (Eralfon® ) of chemotherapy induced anemia. Sovremennaya onkologiya = Journal of Modern Oncology 2017;19(1):80–4. (In Russ.). Available at: https://modernonco.orscience.ru/1815-1434/article/view/27129
16. Krysanov I.S., Makarova E.V., Ermakova V.Yu. Comparative pharmacoeconomic analysis of the use of erythropoiesis-stimulating drugs for the treatment of anemia in cancer patients. Meditsinskiy sovet = Medical Council 2021;(20):174-82. (In Russ.). DOI: 10.21518/2079-701X-2021-20-174–182
17. Larionova V.B., Krysanov I.S., Snegovoy A.V. et al. Rational maintenance therapy for chemotherapy induced anemia: a pharmaco-economic analysis of erythropoietin therapy in cancer patients in Russian Federation. Onkogematologiya = Oncohematology 2018;13(2):48–61. (In Russ.). DOI: 10.17650/1818-8346-2018-13-2-48-61.
18. Krysanov I.S., Krysanova V.S., Ermakova V.Yu. Pharmacoeconomic analysis of anemia therapy in cancer patients in real clinical practice of the Russian Federation. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2018;(4):4–12. (In Russ.). DOI: 10.24411/2588-0519-2018-10054
19. Krysanov I.S., Ermakova V.Y., Vaskova L.B., Tiapkina M.V. Cost-minimization analysis of using short and long-acting erythropoesis-stimulating agents for correction of nephrogenic anemia against the background of substitution therapy. Farmatsiya i farmakologiya = Pharmacy & Pharmacology 2021;9(5):387–99. (In Russ.). DOI: 10.19163/2307-9266-2021-9-5-387-399
Review
For citations:
Chekini J.A. Algorithm of anemia correction in oncological patients. MD-Onco. 2023;3(1):68-72. (In Russ.) https://doi.org/10.17650/2782-3202-2023-3-1-68-72
Views:
635
Email this article 